Clinical Trials Using Erlotinib Hydrochloride
Clinical trials are research studies that involve people. The clinical trials on this list are studying Erlotinib Hydrochloride. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Erlotinib Hydrochloride in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
This phase III ALCHEMIST trial studies how well erlotinib hydrochloride compared to observation works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: 1321 locations
Maintenance Chemotherapy with or without Local Consolidative Therapy in Treating Patients with Stage IV Non-small Cell Lung Cancer
This randomized phase II / III trial studies how well giving maintenance chemotherapy with or without local consolidation therapy works in treating patients with stage IV non-small cell lung cancer. Drugs used in maintenance chemotherapy, such as docetaxel, pemetrexed disodium, erlotinib hydrochloride, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Local consolidation therapy such as radiation / stereotactic body radiation or surgery may kill cancer cells left after initial treatment. Giving maintenance chemotherapy and local consolidation therapy together may work better than maintenance chemotherapy alone in treating patients with stage IV non-small cell lung cancer.
Location: 202 locations
My Pathway: A Study Evaluating Herceptin / Perjeta, Tarceva, Zelboraf / Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and / or are not suitable options per the treating physician's judgment.
Location: 24 locations
Trametinib and Erlotinib Hydrochloride in Treating Patients with Stage IV or Recurrent Lung Cancer with EGFR Activating Mutation
This phase I / II trial studies the side effects of trametinib when given together with erlotinib hydrochloride and to see how well they work in treating patients with lung cancer that has an EGFR activating mutation and is stage IV or has come back. Trametinib and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: 7 locations
A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Subjects With Advanced Solid Tumors
This is a Phase 1 / 1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 as monotherapy and in combination with osimertinib, erlotinib, and nivolumab in subjects with advanced solid tumors likely to express c-Met. Enrollment is closed for the monotherapy arms, Arm A, and Arm D.
Location: 6 locations
A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
A Phase I / 2 multi-center open-label study of BGB324 in combination with erlotinib in patients with Stage IIIb or Stage IV non-small cell lung cancer. BGB324 is a potent selective small molecule inhibitor of Axl, a surface membrane protein kinase receptor which is connected with poor prognosis and acquired resistance to therapy.
Location: 2 locations
Erlotinib Hydrochloride before Surgery in Treating Patients with Stage III Non-Small Cell Lung Cancer
This phase II trial studies how well erlotinib hydrochloride works before surgery in treating patients with stage III non-small cell lung cancer. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving erlotinib hydrochloride before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
Location: 3 locations
Cabozantinib S-Malate and Erlotinib Hydrochloride for Patients with EGFR and C-Met Co-expressing Metastatic Pancreatic Cancer
This phase II trial studies how well cabozantinib S-malate and erlotinib hydrochloride work in treating patients with EGFR and C-Met co-expressing pancreatic cancer that has spread to other places in the body. Cabozantinib S-malate and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: Indiana University / Melvin and Bren Simon Cancer Center, Indianapolis, Indiana
Genetic Testing in Screening Patients with Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
This phase III ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient’s tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
Location: 1393 locations
Erlotinib Hydrochloride in Preventing Liver Cancer in Patients with Cirrhosis of the Liver
This pilot phase I / II trial studies the best dose of erlotinib hydrochloride and to see how well it works in preventing liver cancer in patients with scarring (cirrhosis) of the liver. Erlotinib hydrochloride may help to inhibit the development of fibrous tissue and prevent liver cancer from forming in patients with cirrhosis of the liver.
Location: 6 locations